Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab
Oncology · 2025
DOI: 10.1159/000548964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Michael Sheu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cleveland Clinic, Internal Medicine, Cleveland, Ohio, USA, msheu3@gmail.com. Hauptthemen laut MEDLINE: Immunoglobulins, Intravenous, Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
B-cell maturation antigen-targeting bispecific antibodies such as teclistamab have been associated with increased risk of infections as compared with conventional treatment regimens. This study explored the efficacy of intravenous immunoglobulin (IVIG) prophylaxis in reducing infection-related hospitalizations (IRHs) in MM patients who underwent treatment with teclistamab.
Methods
This was a retrospective study of MM treated with teclistamab at Taussig Cancer Center from December 16, 2022, to March 31, 2024. The primary endpoint was incidence rate of IRHs per patient-day on-IVIG vs. off-IVIG.
Results
Among the 44 patients included in the study, there were 19 infectious episodes that required inpatient hospitalization, occurring among 17 patients. Five infections occurred during 4,378 days during the “on-IVIG” period, compared to 14 infections occurring during 4,619 days for the “off-IVIG” period for an infectious incidence rate ratio between the two groups of 2.65 (p value = 0.027).
Conclusion
Patients treated with bispecific antibodies such as teclistamab are highly susceptible to infections due to impaired humoral immunity and hypogammaglobulinemia. Our findings demonstrate a reduction in infection incidence in patients while receiving IVIG. These results support the use of IVIG as an effective prophylactic strategy to reduce infectious risk in this vulnerable patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cleveland Clinic, Internal Medicine, Cleveland, Ohio, USA, msheu3@gmail.com.
- Mayo Clinic. Infectious Disease, Rochester, New York, USA.
- Cleveland Clinic, Internal Medicine, Cleveland, Ohio, USA.
- Cleveland Clinic, Pharmacy, Cleveland, Ohio, USA.
- Internal Medicine, University of Toronto, Toronto, Ontario, Canada.
- Cleveland Clinic, Hematology and Medical Oncology, Cleveland, Ohio, USA.
Zitieren
APA
Sheu, M., Molina Garcia, S., Patel, M., Mushtaq, A., Rust, T., Anns Asif, M., Anwer, F., & Majeed, A. (2025). Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab. Oncology. https://doi.org/10.1159/000548964
Vancouver
Sheu M, Molina Garcia S, Patel M, Mushtaq A, Rust T, Anns Asif M, et al. Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab. Oncology. 2025. doi:10.1159/000548964
BibTeX
@article{Sheu2025,
author = {Sheu, Michael and Molina Garcia, Sofia and Patel, Meera and Mushtaq, Ali and Rust, Thomas and Anns Asif, Muhammad and Anwer, Faiz and Majeed, Aneela},
title = {Infection Prophylaxis with Intravenous Immunoglobulin in Multiple Myeloma Patients Treated with Teclistamab},
journal = {Oncology},
year = {2025},
doi = {10.1159/000548964}
}
EUVIMED